4.5 Article

Design evaluation and optimization for models of hepatitis C viral dynamics

Journal

STATISTICS IN MEDICINE
Volume 30, Issue 10, Pages 1045-1056

Publisher

WILEY
DOI: 10.1002/sim.4191

Keywords

design evaluation; design optimization; hepatitis C; non-linear mixed effect models; ordinary differential equations; viral kinetics

Funding

  1. French Ministry of Foreign Affairs
  2. Israel Science Foundation [ISF 939/2008]
  3. US Department of Energy [RR06555, P20-RR18754]

Ask authors/readers for more resources

Mathematical modeling of hepatitis C viral (HCV) kinetics is widely used for understanding viral pathogenesis and predicting treatment outcome. The standard model is based on a system of five non-linear ordinary differential equations (ODE) that describe both viral kinetics and changes in drug concentration after treatment initiation. In such complex models parameter estimation is challenging and requires frequent sampling measurements on each individual. By borrowing information between study subjects, non-linear mixed effect models can deal with sparser sampling from each individual. However, the search for optimal designs in this context has been limited by the numerical difficulty of evaluating the Fisher information matrix (FIM). Using the software PFIM, we show that a linearization of the statistical model avoids most of the computational burden, while providing a good approximation to the FIM. We then compare the precision of the parameters that can be expected using five study designs from the literature. We illustrate the usefulness of rationalizing data sampling by showing that, for a given level of precision, optimal design could reduce the total number of measurements by up 50 per cent. Our approach can be used by a statistician or a clinician aiming at designing an HCV viral kinetics study. Copyright (C) 2011 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Mathematical & Computational Biology

Efficient model-based bioequivalence testing

Kathrin Moellenhoff, Florence Loingeville, Julie Bertrand, Thu Thuy Nguyen, Satish Sharan, Liang Zhao, Lanyan Fang, Guoying Sun, Stella Grosser, France Mentre, Holger Dette

Summary: The classical approach for analyzing pharmacokinetic (PK) data in bioequivalence studies is noncompartmental analysis (NCA) followed by two one-sided tests (TOST). However, a model-based alternative has been proposed for sparse designs. In this study, a more powerful test is proposed and demonstrated to be superior to TOST through simulation studies for both NCA and model-based approaches. This method shows potential use in situations where conventional bioequivalence analysis is not applicable, especially for products with high PK parameter variability.

BIOSTATISTICS (2022)

Editorial Material Infectious Diseases

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group

Alpha Diallo, Marius Troseid, Victoria Charlotte Simensen, Anais Boston, Jacques Demotes, Inge Christoffer Olsen, Florence Chung, Jose Artur Paiva, Maya Hites, Florence Ader, Jose Ramon Arribas, Andreas Baratt-Due, Oyvind Melien, Evelina Tacconelli, Therese Staub, Richard Greil, Sotirios Tsiodras, Matthias Briel, Helene Esperou, France Mentre, Joe Eustace, Juliette Saillard, Christelle Delmas, Soizic LeMestre, Marina Dumousseaux, Dominique Costagliola, John-Arne Rottingen, Yazdan Yazdanpanah

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Article Infectious Diseases

An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones

Maria J. G. T. Vehreschild, Annie Ducher, Thomas Louie, Oliver A. Cornely, Celine Feger, Aaron Dane, Marina Varastet, Fabien Vitry, Jean de Gunzburg, Antoine Andremont, France Mentre, Mark H. Wilcox

Summary: DAV132 showed good tolerability and did not affect FQ plasma concentrations in hospitalized patients receiving FQ treatment. DAV132 preserved intestinal microbiota diversity and resistance to C. difficile colonization.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Article Infectious Diseases

High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea

Philippine Eloy, Cedric Laouenan, Abdoul Habib Beavogui, Sakoba Keita, Pauline Manchon, Jean-Francois Etard, Daouda Sissoko, France Mentre, Denis Malvy

Summary: The study aimed at evaluating the tolerance and activity of high doses of favipiravir in male EVD survivors with EBOV RNA detection in semen in Guinea. However, only two participants were included due to recruitment difficulties, and no clinical adverse events of grade 3/4 were reported for both patients.

IDCASES (2022)

Article Infectious Diseases

Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial

Guillaume Lingas, Nadege Neant, Alexandre Gaymard, Drifa Belhadi, Gilles Peytavin, Maya Hites, Therese Staub, Richard Greil, Jose-Artur Paiva, Julien Poissy, Nathan Peiffer-Smadja, Dominique Costagliola, Yazdan Yazdanpanah, Florent Wallet, Amandine Gagneux-Brunon, France Mentre, Florence Ader, Charles Burdet, Jeremie Guedj, Maude Bouscambert-Duchamp

Summary: Remdesivir reduces viral production, leading to a 0.7-day reduction in the time to viral clearance. It has a larger impact in patients with high viral load at randomization.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Article Virology

Variant-specific SARS-CoV-2 within-host kinetics

Baptiste Elie, Benedicte Roquebert, Mircea T. Sofonea, Sabine Trombert-Paolantoni, Vincent Foulongne, Jeremie Guedj, Stpehanie Haim-Boukobza, Samuel Alizon

Summary: This study analyzed a longitudinal cohort in France and found that infections caused by the Alpha variant have a higher number of viral genome copies and a slower decay rate, leading to significantly higher transmission potentials, especially in older populations. There was no significant difference in peak viral copy number between infections caused by the Alpha and Delta variants.

JOURNAL OF MEDICAL VIROLOGY (2022)

Article Pharmacology & Pharmacy

Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation

Jinju Guk, Antoine Bridier-Nahmias, Melanie Magnan, Nathalie Grall, Xavier Duval, Olivier Clermont, Etienne Ruppe, Camille d'Humieres, Olivier Tenaillon, Erick Denamur, France Mentre, Jeremie Guedj, Charles Burdet

Summary: Recent studies have emphasized the importance of ecological interactions in dysbiosis of gut microbiota. This study aimed to investigate the role of ecological interactions in antibiotic-induced perturbations. The results showed that considering bacterial interactions and individual antibiotic exposure profile can improve the analysis of antibiotic-induced dysbiosis.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)

Letter Infectious Diseases

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation

Xavier de Lamballerie, Guillaume Martin-Blondel, Axelle Dupont, Jacques Izopet, France Mentre, Nassim Kamar, Brigitte Autran, Gilles Paintaud, Sophie Caillard, Amandine le Bourgeois, Christophe Richez, Lionel Couzi, Alienor Xhaard, Zora Marjanovic, Jerome Avouac, Caroline Jacquet, Denis Anglicheau, Morgane Cheminant, Yazdan Yazdanpanah, Stephanie N. Guyen, Benjamin Terrier, Jacques Eric Gottenberg, Caroline Besson, Sophie Letrou, Sabrina Kali, Denis Angoulvant, Ventzislava Petrov Sanchez, Coralie Tardivon, Gilles Blancho, Vincent Levy

JOURNAL OF INFECTION (2023)

Article Pharmacology & Pharmacy

Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies

Melanie Guhl, Francois Mercier, Carsten Hofmann, Satish Sharan, Mark Donnelly, Kairui Feng, Wanjie Sun, Guoying Sun, Stella Grosser, Liang Zhao, Lanyan Fang, France Mentre, Emmanuelle Comets, Julie Bertrand

Summary: This study evaluated the performance of pharmacokinetic equivalence testing using a model-based approach, MB-TOST, which showed more robust results in cases of model misspecification and was reliable in sparse designs when the PK structural model was correctly specified.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2022)

Article Pharmacology & Pharmacy

Joint modeling under competing risks: Application to survival prediction in patients admitted in Intensive Care Unit for sepsis with daily Sequential Organ Failure Assessment score assessments

Alexandra Lavalley-Morelle, Jean-Francois Timsit, France Mentre, Jimmy Mullaert

Summary: This study proposes a novel method for full parametric joint estimation of longitudinal process and time-to-event data in the presence of competing risks, aiming to provide individualized dynamic predictions. Simulation study and validation set demonstrate that joint modeling offers better predictions for death, providing a new approach for clinical applications.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon

Selma El Messaoudi, Annabelle Lemenuel-Diot, Antonio Goncalves, Jeremie Guedj

Summary: This study developed a mathematical model to evaluate the effects of antiviral treatments against hepatitis B virus. The results showed that lamivudine had a stronger effect in blocking viral production compared to pegylated interferon. Moreover, pegylated interferon had a significant immunomodulatory effect.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

Evaluation of model-based bioequivalence approach for single sample pharmacokinetic studies

Coralie Tardivon, Florence Loingeville, Mark Donnelly, Kairui Feng, Wanjie Sun, Guoying Sun, Stella Grosser, Liang Zhao, Lanyan Fang, France Mentre, Julie Bertrand

Summary: In a traditional PK BE study, PK parameters are obtained through noncompartmental analysis and BE analysis is performed using TOST. However, for ophthalmic drugs, the limited sample availability makes traditional analysis difficult. The FDA has proposed using NCA bootstrap and MB-TOST as alternative approaches. Simulation studies showed that MB-TOST performed similarly to NCA bootstrap for AUC and was a potentially better choice for C-max.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2023)

Article Biochemical Research Methods

Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2

Quentin Clairon, Melanie R. Prague, Delphine R. Planas, Timothee R. Bruel, Laurent R. Hocqueloux, Thierry R. Prazuck, Olivier R. Schwartz, Rodolphe R. Thiebaut, Jeremie R. Guedj

Summary: Due to the constant mutations of SARS-CoV-2, neutralizing capacity of antibodies targeting the historical strain decreases against emerging Variants of Concerns (VoCs). The study utilized a mathematical model to analyze the humoral response in individuals who received up to three doses of the Bnt162b2 vaccine. It was found that the neutralization capacity significantly increased after the third dose, providing prolonged protection against different VoCs.

PLOS COMPUTATIONAL BIOLOGY (2023)

Article Pharmacology & Pharmacy

Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer

Antonio Goncalves, Mathilde Marchand, Phyllis Chan, Jin Y. Jin, Jeremie Guedj, Rene Bruno

Summary: This study compared two main approaches, two-stage and joint modeling, to investigate the link between tumor size data and overall survival. The results showed that both approaches accurately predicted the benefit of atezolizumab in non-small cell lung cancer patients.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2023)

Letter Infectious Diseases

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, France Mentre, Charles Burdet

LANCET INFECTIOUS DISEASES (2022)

No Data Available